 Research Hypothesis DPP-4 inhibition by saxagliptin ONGLYZATM reduces adipose tissue inflammation in obese individuals and this is characterized by decreases in a reactive oxygen species ROS production, b toll-like receptors TLR and NF-kappa B pathway activation, c expression of pro-inflammatory genes, d macrophage infiltration, and e secretion of pro-inflammatory factors. 